News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mark E. Davis Presents Information About Cerulean Pharma Inc. (CERU)'s Lead Candidate, CRLX101, At 2014 American Society of Clinical Oncology Annual Meeting


6/10/2014 9:21:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced that Mark E. Davis, Ph.D., Professor of Chemical Engineering at the California Institute of Technology, presented information about Cerulean's lead candidate, CRLX101, in a presentation entitled "Nanoparticle Delivery Platform for Solid Tumors" at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago on Monday, June 2nd.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES